Pancreas cancer harbors cells in different states, with classical cells (red) and basal cells (turquoise) co-existing within individual tumors. Basal cells, which typically are associated with aggressive disease, show increased sensitivity to KRAS inhibitors, a promising new drug class for pancreatic cancer. Credit: Memorial Sloan Kettering Cancer Center Mutations in the KRAS gene are the primary driver of pancreatic cancer. A new class of drugs known as KRAS inhibitors is showing initial promise in clinical trials, but many tumors quickly develop resistance to the treatment. Now, researchers at Memorial Sloan Read More